Hackensack

North East Regional Epilepsy Group

Myelodysplastic Syndromes

B-Cell Lymphoma

Leukemia

Preleukemia

Non-Hodgkin Lymphoma

Acute Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Lymphoma

Syndrome

Diffuse Large B-Cell Lymphoma

ASTX727

Decitabine

CMX001

Astex Pharmaceuticals

Chimerix

Lyell Immunopharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

North East Regional Epilepsy Group | Hackensack

Site insights

Work at this site?

Active trials

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PiNACLE-H2H)

Trial sponsors